Celiac Disease Clinical Trial
Official title:
Tissue Destruction and Healing in Celiac Disease
The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on celiac disease clinical symptoms, and severity of tissue destruction and its ability to heal in individuals with celiac disease. Information collected in the study will help researchers to generate better resources to advance celiac disease patient care.
Celiac disease is an autoimmune enteropathy characterized by chronic inflammation of the small intestinal mucosa triggered by gluten uptake that occurs in genetically susceptible individuals carrying the specific class II human leucocyte antigens (HLA) DQ2 and DQ8 alleles. There is a spectrum in intestinal tissue damage associated with celiac disease. Some individuals develop inflammatory immunity in the absence of tissue damage, while others experience tissue damage ranging from partial to total villous atrophy. Persistent mucosal damage is associated with several severe complications, including lymphoproliferative malignancy and bone diseases. In addition, individuals with active celiac disease display a wide range of clinical symptoms, including metabolic defects that are not correlated to the degree of villous atrophy. Although much progress has been made in understanding celiac disease, major gaps remain in understanding biological mechanisms underlying inter-individual differences in clinical presentations and capacity to heal while maintaining a gluten-free diet. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04349904 -
Near-Focus NBI Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation
|
||
| Recruiting |
NCT05581628 -
FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
|
||
| Completed |
NCT04593251 -
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
|
Phase 1 | |
| Completed |
NCT05810441 -
Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
|
||
| Recruiting |
NCT05555446 -
Bovine Colostrum to Prevent Absorption of Gluten
|
Early Phase 1 | |
| Completed |
NCT02754609 -
Hookworm Therapy for Coeliac Disease
|
Phase 1 | |
| Terminated |
NCT01902368 -
Celiac Disease Screening
|
N/A | |
| Completed |
NCT02472704 -
Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo
|
N/A | |
| Completed |
NCT02312349 -
Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City
|
||
| Recruiting |
NCT01172665 -
Celiac Disease Database
|
||
| Completed |
NCT01100099 -
HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT00639444 -
Risk of Celiac Disease and Age at Gluten Introduction
|
N/A | |
| Recruiting |
NCT05425446 -
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
|
Phase 1 | |
| Enrolling by invitation |
NCT02202681 -
Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule
|
N/A | |
| Completed |
NCT00362856 -
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
|
Phase 2 | |
| Terminated |
NCT03866538 -
Budesonide in Patients With Immune Mediated Enteropathies
|
Phase 4 | |
| Recruiting |
NCT05135923 -
Glutenfree, Gut Microbiota and Metabolic Regulation
|
N/A | |
| Completed |
NCT05052164 -
Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women
|
N/A | |
| Completed |
NCT03775499 -
Probiotic BL NCC 2705 and Gluten Sensitivity
|
N/A | |
| Completed |
NCT03707730 -
A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease
|
Phase 2 |